To undertake an in‐depth exploration of the expectations and experiences of adults with T2DM regarding GLP‐1 RA use and (dis)continuation, as well as attitudes toward further injectable treatment intensification. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.